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Purpose: To prescribe different physical activity (PA) intensities using activity trackers to 
increase PA, reduce sedentary time, and improve health outcomes among breast cancer 
survivors. The maintenance effect of the interventions on study outcomes was also assessed. 
Methods: The Breast Cancer and Physical Activity Level pilot trial randomized 45 breast cancer 
survivors to a home-based, 12-wk lower (300 min·wk−1 at 40%–59% of HR reserve) or higher-
intensity PA (150 min·wk−1 at 60%–80% of HR reserve), or no PA intervention/control. Both 
intervention groups received Polar A360® activity trackers. Study outcomes assessed at baseline, 
12 and 24 wk included PA and sedentary time (ActiGraph GT3X+), health-related fitness (e.g., 
body composition, cardiopulmonary fitness/VO2max), and patient-reported outcomes (e.g., quality 
of life). Intention-to-treat analyses were conducted using linear mixed models and adjusted for 
baseline outcomes. Results: Increases in moderate-vigorous intensity PA (least squares adjusted 
group difference [LSAGD], 0.6; 95% confidence interval [CI], 0.1–1.0) and decreases in 
sedentary time (LSAGD, −1.2; 95% CI, −2.2 to −0.2) were significantly greater in the lower-
intensity PA group versus control at 12 wk. Increases in VO2max at 12 wk in both interventions 
groups were significantly greater than changes in the control group (lower-intensity PA group 
LSAGD, 4.2; 95% CI, 0.5–8.0 mL·kg−1·min−1; higher-intensity PA group LSAGD, 5.4; 95% 
CI, 1.7–9.1mL·kg−1·min−1). Changes in PA and VO2max remained at 24wk, but differences 
between the intervention and control groups were no longer statistically significant. 
Conclusions: Increases in PA time and cardiopulmonary fitness/VO2max can be achieved with 
both lower- and higher-intensity PA interventions in breast cancer survivors. Reductions in 
sedentary time were also noted in the lower-intensity PA group. 
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As breast cancer survivors live longer, more women are seeking ways to improve their quality of 
life after diagnosis, and increasing physical activity (PA) and decreasing sedentary time are 
being viewed as means to achieve this objective. The American Cancer Society (1,2) and the 
American College of Sports Medicine (3) advise cancer survivors to engage in at least 150 
min·wk-1 of moderate- to vigorous-intensity (40%-85% of HR reserve [HRR]) (4) PA and limit 
total sitting time for overall health and well-being. These guidelines are based on convincing 
evidence that PA and limiting sitting time during or after cancer treatment improves quality of 
life, muscular and aerobic fitness, and does not cause harm (1-3). Despite these 
recommendations, research in Canada (5) and the United States (6-8) suggests that the majority 
of breast cancer survivors are not sufficiently active, spending on average 65% to 80% of their 
time awake being sedentary and only 2% to 3% of their time as moderate- to vigorous-intensity 
PA. These rates of physical inactivity and high sedentary time are concerning given evidence 
that low levels of PA and/or high amounts of sedentary time are associated with increased risks 
of cancer recurrence and mortality (9-12). 
 
A recent meta-analysis of randomized controlled trials (RCT) including home-based PA 
interventions in posttreatment cancer survivors reported an overall small effect size of 0.21 
favoring the PA intervention versus usual care for improvements in moderate-vigorous intensity 
PA time (13). Another systematic review (14) reported improvements in cardiorespiratory fitness 
and muscular strength after aerobic and/or resistance PA interventions in breast cancer survivors. 
Three systematic reviews have also assessed the effects of PA interventions on patient-reported 
outcomes, reporting that PA interventions lead to greater improvements in patient-reported 
outcomes compared to conventional interventions/usual care (15-17). Finally, some (18-22), but 
not all (23,24), studies have reported associations between high levels of sedentary time and/or 
low sit-to-stand transitions with markers of health-related fitness and patient-reported outcomes 
in breast cancer survivors. Additional research is needed to establish interventions aimed at 
reducing sedentary time and its impact on health outcomes in breast cancer survivors. 
 
Despite strong evidence for improvements in markers of health-related fitness and patient-
reported outcomes after PA interventions of at least moderate-intensity (3,14-17), a recent study 
reported that breast cancer survivors with the lowest self-reported PA levels expressed more 
barriers to PA participation and consistently preferred light- to moderate-intensity PA, whereas 
more active women preferred moderate- to vigorous-intensity PA (25). Hence, promoting lower-
intensity PA (40%-59% of HRR, or lower end of moderate-intensity PA (4)) could be a 
successful means for improving adherence and reducing barriers to PA participation in 
physically inactive breast cancer survivors. Evidence is needed to assess differences in adherence 
and feasibility to achieving PA goals based on a prescription of lower (40%-59% of HRR) versus 
higher (60%-80% of HRR, or higher end of moderate/vigorous-intensity PA (4)) intensity PA in 
this population. 
 
Few RCT to date have also tested the efficacy of newer forms of technology, such as mobile 
technologies and wearable activity trackers, to deliver PA interventions in cancer survivors 
(13,26). Specifically, wearable activity trackers use self-monitoring strategies to prompt behavior 
change by providing automated feedback on sedentary time and PA of different intensities. 
These devices are low cost and have potential for scalable use in behavioral interventions that 
promote both reductions in sedentary time and increases in PA (27,28). Breast cancer survivors, 
specifically, have also expressed an interest in using wearable activity trackers to self-monitor 
physical activity and sedentary time (28,29). Initial intervention studies using wearable activity 
trackers have shown improvements in PA (30-33), reductions in sedentary time (32,34), as well 
as improved sleep quality (35), self-reported quality of life (32-34), and cardiorespiratory fitness 
(30). However, only one study (36) utilized measures from the wearable activity trackers to 
assess adherence to the intervention and another (34) assessed changes in study outcomes at 
follow-up. Furthermore, no RCT to date has assessed the efficacy of using wearable activity 
trackers to prescribe PA intensity based on HRR among inactive breast cancer survivors. 
 
To develop the methods for and establish the feasibility of a full scale trial, we conducted pilot 
data collection in 45 breast cancer survivors. The aim of the Breast Cancer and Physical Activity 
Level (BC-) pilot trial was to assess the effects of prescribing 300 min·wk-1 of lower-intensity 
PA (40%-59% of HRR) or 150 min·wk-1 of higher-intensity PA (60%-80% of HRR) for 12 wk 
using wearable activity trackers, compared to no PA intervention/control, on objective measures 
of PA and sedentary time, as well as markers of health-related fitness and patient reported 
outcomes, in physically inactive breast cancer survivors. This study also evaluated the longer-
term (24 wk) maintenance effect of these interventions on study outcomes. Lastly, this study 
assessed differences in adherence to wearing the activity tracker and achieving the prescribed PA 
prescriptions between both intervention groups. 
 
MATERIALS AND METHODS 
 
Setting and participants 
 
This single-center, three-armed, 12-wk pilot RCT was conducted in Calgary (Alberta, Canada) 
between February 2017 and April 2018. Participants were recruited through the Alberta Cancer 
Registry, a population-based registry which receives information on all cancer cases diagnosed 
throughout Alberta from physicians and laboratories. The Alberta Cancer Registry mailed 
invitation letters from the study investigators, a copy of the study consent form and a study 
brochure to 900 randomly selected breast cancer survivors who were residing in the Calgary area 
at the time of recruitment. Breast cancer survivors who were interested in receiving more 
information and/or participating in the study were invited to contact the study team. Of the 109 
individuals who contacted the study team, 53 completed baseline assessments and 45 were 
randomized to one of three groups: 1) lower-intensity PA intervention, 2) higher-intensity PA 
intervention, or 3) no PA intervention (control). Eligibility criteria included: females 18 yr or 
older; diagnosed with histologically confirmed stage I-IIIc breast cancer; completion of adjuvant 
treatment (chemotherapy, radiation therapy, and surgery) except for hormonal therapy; 
nonpregnant; recreationally inactive (accumulating <=60 min of moderate-vigorous intensity PA 
per week and <=10,000 steps per day); able to undertake a PA program and received medical 
clearance from a physician if the potential participant had medical conditions that may impede 
safe PA participation (e.g., severe arthritis, spinal cord injury, heart or cardiovascular disease); 
currently living in the Calgary area and able to meet with study staff at the Holy Cross Centre in 
Calgary on six occasions for data collection. All eligibility criteria were first assessed by self-
report over the phone. Further assessment of PA levels was completed at baseline by verifying 
accelerometry data and providing a pedometer to wear for 7 d if participants reported achieving 
>=10,000 steps or >=60 min·wk-1 of PA on occasion or reported having an "active" employment 
(e.g., housekeeping). Information on breast cancer stage at diagnosis and the type of treatments 
received were also verified through electronic medical records maintained by the Department of 
Cancer Surveillance within CancerControl Alberta, Alberta Health Services. The study protocol 
was conducted according to the guidelines laid down in the Declaration of Helsinki, and all 
procedures involving human participants were approved by the Health Research Ethics Board of 
Alberta-Cancer Committee. Written informed consent was provided by all participants. 
 
Physical activity interventions 
 
Participants randomized to the lower- and higher-intensity PA interventions were instructed to 
accumulate 300 min·wk-1 of PA at an intensity of 40% to 59% of HRR (~3-5 METs) or 150 
min·wk-1 of PA at an intensity of 60% to 80% of HRR (~6-9 METs), respectively (4,37). The 
total PA volume prescribed to each group was similar (~15-25 MET·h·wk-1). Participants 
randomized to these PA interventions were given a wrist-worn Polar A360(R) device to record 
HR/PA intensity and PA duration throughout the intervention. The target PA intensity was 
individualized for each participant based on calculated HRR: [(HRmax - HRrest) x exercise 
intensity (%)] + HRrest. HRmax was estimated based on the following equation: 220 - age. This 
target PA intensity was programmed under the "training" application of this wearable activity 
tracker. Any aerobic activity that raises the HR into the target HR zone was counted as PA time, 
including household and short PA bouts (i.e., <10 min). This activity tracker also provided 
prompt feedback on HR/PA intensity and PA duration that could be used by participants to 
modify their home-based/unsupervised PA participation. Participants were instructed to upload 
their data to the Polar Flow(R) application at least once per week to minimize the risk of missing 
data and to allow the Study Exercise Physiologist to track their progress. 
 
As part of the PA interventions, these participants also received a diary with questions on goal 
setting, the feasibility of the prescribed PA targets, and strategies and barriers to PA 
participation, which they were instructed to complete every 3 wk to facilitate active follow-up 
discussions by phone or e-mail with the Study Exercise Physiologist. These active follow-up 
discussions were used to review data from the Polar A360(R) device and diary, to reinforce 
adherence, and discuss any problems/barriers to achieving the prescribed PA goals. 
 
Participants randomized to the control group were instructed to maintain their baseline PA levels 





Participants were aware that all study outcome assessments would be repeated at the 24-wk 
timepoint. However, PA participation was not monitored, nor did participants receive a PA 
prescription during the follow-up period. Participants randomized to either of the PA 
interventions were able to retain their Polar A360(R) device as an incentive for study 
participation, but its use during this follow-up period was discretionary. Participants randomized 
to the control group received the written resources from the interventions, a personal PA 
prescription from the Study Exercise Physiologist and a wrist-worn activity tracker as an 
incentive for study participation at the end of the follow-up period. All participants also received 
personalized results for all outcome measurements after their involvement in the study and were 
able to discuss these results and pose any questions that they may have with the Study Exercise 




All outcomes were assessed at baseline, just before the end of the intervention (12 wk) and at end 
of follow-up (24 wk). Our primary outcomes included total, moderate-vigorous and light- 
intensity PA times, as well as sedentary and sleep times, assessed with the ActiGraph(R) GT3X+ 
accelerometer (ActiGraph LLC, Pensacola, FL). All participants were asked to wear this 
accelerometer around their waist for 24 h·d-1 (except for water-based activities because this 
device is not waterproof) for seven consecutive days. Accelerometry data were collected from 
the ActiGraph(R) GT3X+ device at a sampling rate of 80 Hz and were aggregated to 60-s epoch 
files for analysis by the ActiLife(R) software (v6.10.2). We used the Actigraph(R) Vertical Axis 
(VT) calculations (38) to derive PA and sedentary time outcomes from the accelerometry-
measured activity counts. The following cutpoints, which were initially calibrated against a 
broad range of lifestyle and ambulatory activities assessed under free-living conditions (39), 
were used to define PA time according to intensity and sedentary time for the VT calculations: 
<100 counts per minute (sedentary), 100 to 760 counts per minute (light intensity) and >760 
counts per minute (moderate-vigorous intensity). These cutoff points were also recently shown to 
provide more accurate estimates of moderate- to vigorous-intensity PA time by capturing a 
broader range of activities under free-living conditions (40). To identify nonwear and sleep 
times, an automated algorithm developed by McVeigh et al. (41) using only counts per minute 
VT data from hip-worn Actigraph(R) accelerometers was used. This algorithm first attempts to 
identify long periods of in-bed time by searching for prolonged periods of low activity (>=180 
min at <89 counts per minute). The algorithm then searches for sustained periods of higher-
intensity activity (>=10 min at >=89 counts per minutes), which is assumed to be the time the 
participant arose from bed/woke up. To determine exact bed and wake times, the algorithm 
searches for the 30 min before and after this prolonged sleep period and identifies bedtime as the 
first minute with an activity count <=89 counts per minute that follows 10 min containing >=4 
min with activity counts <=50. Wake time is identified as the first minute with >=91 counts per 
minute followed by 10 min containing >=3 min with activity counts >200. Time in bed (assumed 
sleeping time) is then calculated as the elapsed time between bed and wake times (41). 
 
Our secondary outcomes included markers of health-related fitness. Specifically, anthropometric 
data, which include standing height, weight, waist, and hip circumferences, were measured using 
standard equipment and methods established by the Canadian Society for Exercise Physiology 
(42). A dual X-ray absorptiometry scan (Hologic(R) system, Marlborough, MA) with a full body 
image was used to estimate total lean body mass (kg) and fat mass (kg). The multistage, 
submaximal Balke treadmill test was used to estimate cardiorespiratory fitness in all participants. 
During this treadmill test, participants walked at a speed of 3 mph with a gradient starting at 0% 
which increased by 2.5% every 3 min until they reached 85% of predicted maximal HR. This test 
is considered safe for individuals with low PA levels because the elevation in workload is 
moderate (43). Measurements during this test included: test duration (minutes), HR at rest and 
during exercise assessed with a HR monitor, blood pressure at rest and during exercise assessed 
with a blood pressure cuff and sphygmomanometer, and ratings of perceived exertion assessed 
with a Borg scale. The following formula developed by Pollock et al. (43) in women was used to 
estimate participants' V̇O2max: V̇O2max = [1.38 x test duration (minutes) + 5.22]. 
 
Self-administered questionnaires were used to assess patient reported outcomes. These included: 
sleep quality (Pittsburgh Sleep Quality Index (44)); health-related quality of life (the Medical 
Outcomes Study Short Form-12 survey (45)); breast cancer-specific quality of life and symptoms 
including body image, breast and arm pain (The Functional Assessment of Cancer Therapy-
Breast (46)); feelings of happiness (the Happiness Measures (47)); and perceived feelings of 




A two-tailed independent means sample size calculation with 80% power and α = 0.05 based on 
moderate-intensity walking time measured with accelerometry (control group, 11.5 +/- 8.7 vs 
walking intervention group, 26.3 +/- 14.0 min·d-1) after a 12-wk RCT aimed at increasing PA 
participation in inactive breast cancer survivors (49) provided a target sample size of 11 
participants per group. An additional four participants per group were added to account for 
attrition. 
 
All analyses were performed using SAS (SAS Enterprise Guide Version 7.13 for Linux; SAS 
Institute Inc.). An intention-to-treat analysis that included all participants with complete outcome 
data at baseline, 12 and 24 wk regardless of protocol adherence was used. Independent t-tests 
were used to assess differences between intervention groups in the number of intervention weeks 
with activity tracker data and the percentage of participants who achieved the prescribed amount 
of PA within the targeted HRR zone. Repeated-measures ANOVA tests were also conducted to 
assess any changes across time (weeks 1-3, 4-6, 7-9, and 10-12) in the relative number of 
participants who achieved the prescribed amount of PA and the absolute amount of PA 
accumulated within the prescribed HRR zones for each intervention group. Linear models 
estimated changes in study outcomes within each group at 12 and 24 wk, compared with 
baseline, after adjusting for baseline outcome values. These models also tested the null 
hypothesis of no differences between randomization groups using an ANCOVA test (adjusted for 
baseline outcome values), as well as differences in outcome changes between the lower-intensity 
PA versus the control groups, and the higher-intensity PA versus the control groups, using least 
squares means. The same model was used in an exploratory analysis to test changes in study 
outcomes and differences between groups at 24 wk compared with 12 wk after adjusting for 12-
wk outcome values. Statistical significance was set at α < 0.05, which remained for all analyses 




The number of invited and eligible participants, reasons for exclusion from randomization, and 
the number of participants with complete outcome data are presented in Figure 1. Two 
participants in the control group dropped out of the study and two participants refused or were 
unable to participate in follow-up assessments, meaning that 43 and 41 participants completed 
outcome assessments at 12 and 24 wk, respectively. Baseline characteristics for all participants 
(n = 45) are presented in Table 1. 
 
 
FIGURE 1. CONSORT diagram; the flow of participants through the BC-PAL pilot trial, 
Calgary, Alberta, Canada, 2017-2018. *Participants either refused to complete this component of 
testing or were unable to complete this component of testing due to injury unrelated to study 
participation. 
 
Results collected from the Polar A360(R) activity trackers for each week of the intervention in 
the lower- and higher-intensity PA groups are presented in Figure 2. Polar A360(R) activity 
tracker data were available for participants randomized to the lower- and higher-intensity PA 
groups on 11.7 +/- 0.6 and 11.4 +/- 1.4 interventions weeks, respectively (P = 0.40). The HR 
data were available for the entire 12-wk intervention in 26 of 30 participants (12 participants 
randomized to each intervention group). Over the entire 12-wk intervention, the relative number 
of participants who achieved the prescribed amount of PA within the target HR zone was 
significantly higher in the lower-intensity versus higher-intensity PA group (96% +/- 5% vs 49% 
+/- 35%; P < 0.0001). Participants in the lower-intensity PA group also averaged 928 +/- 520 
min·wk-1 (133 +/- 74 min·d-1) within the prescribed HR zone of 40% to 59% of HRR, and 
participants in the higher-intensity PA group averaged 166 +/- 101 min·wk-1 (24 +/- 14 min·d-1) 
within the prescribed HR zone of 60% to 80% of HRR. There were no statistically significant 
differences in the relative number of participants who achieved the prescribed PA amounts 
across time in the lower-intensity (weeks 1-3, 93% +/- 14%; weeks 4-6, 100% +/- 0%; week 7-9, 
96% +/- 12%; weeks 10-12, 93% +/- 14%; P = 0.35) and higher-intensity (weeks 1-3, 51% +/- 
47%; weeks 4-6, 49% +/- 43%; weeks 7-9, 44% +/- 43%; weeks 10-12, 40% +/- 40%; P = 0.77) 
PA groups. Similarly, there were no statistically significant differences in the absolute amount of 
PA accumulated within the prescribed HRR zone across time in the lower-intensity (weeks 1-3, 
981 +/- 548 min·wk-1; weeks 4-6, 917 +/- 500 min·wk-1; weeks 7-9, 986 +/- 555 min·wk-1; 
weeks 10-12, 1013 +/- 543 min·wk-1; P = 0.78) and higher-intensity (weeks 1-3: 168 +/- 111 
min·wk-1, weeks 4-6: 135 +/- 85 min·wk-1, weeks 7-9: 159 +/- 144 min·wk-1, weeks 10-12: 144 
+/- 109 min·wk-1; P = 0.75) PA groups. 
 
TABLE 1. Baseline participant characteristics, the breast cancer and physical activity level (BC-
PAL) pilot study (n = 45). 
Characteristics 
Control Group 
(n = 15) 
Lower-Intensity PA 
Group (n = 15) 
Higher-Intensity PA 
Group (n = 15) 
Age (yr ± SD) 60 ± 9 58 ± 9 58 ± 10 
Time since end of treatment (d): mean ± SD 1009 ± 570 749 ± 643 1422 ± 1340 
Cancer stage at diagnosis    
Stage I; n (%) 6 (40.0) 7 (46.7) 4 (26.7) 
Stage II; n (%) 6 (40.0) 4 (26.7) 10 (66.7) 
Stage III; n (%) 3 (20.0) 4 (26.7) 1 (6.7) 
Cancer treatment(s) received    
Surgery; n (%) 15 (100.0) 15 (100.0) 15 (100.0) 
Chemotherapy; n (%) 11 (73.3) 13 (86.7) 12 (80.0) 
Radiation treatment; n (%) 12 (80.0) 12 (80.0) 12 (80.0) 
Hormonal therapy; n (%) 11 (73.3) 12 (80.0) 13 (86.7) 
Marital status    
Married or common law; n (%) 11 (73.3) 11 (73.3) 13 (86.7) 
Other; n (%) 4 (26.6) 4 (26.7) 2 (13.3) 
Education    
≤High school; n (%) 2 (13.3) 3 (20.0) 3 (20.0) 
≥Postsecondary school; n (%) 13 (86.7) 12 (80.0) 12 (80.0) 
Ethnicity    
White, n (%) 11 (73.3) 12 (80.0) 13 (86.7) 
Other, n (%) 4 (26.7) 3 (20.0) 2 (13.3) 
Total household income    
<US $50,000; n (%) 30 (20.0) 1 (6.7) 0 (0.0) 
US $50,000–100,000; n (%) 5 (33.3) 6 (40.0) 8 (53.3) 
>US $100,000; n (%) 3 (20.0) 6 (40.0) 7 (46.7) 
Prefer not to disclose or I do not know; n (%) 4 (26.7) 2 (13.3) 0 (0.0) 
 
TABLE 2. Changes in accelerometry-derived physical activity, sedentary and sleep times (baseline to 12 wk) in the lower- and 
higher-intensity PA groups compared with control in the BC-PAL pilot study, Calgary, Alberta, Canada, 2017-2018. 
Outcome Measure Baseline M (SD) 12 wk, M (SD) 
Adjusted Mean 
Change a M (95% CI) Pb Pc 
LS Adjusted Group 
Differencesa M(95% CI) Pd 
Total PA timee (min·d-1)        
Control (n = 13) 318 (108) 348 (96) 24 (–12 to 60) 0.22 0.18   
Lower-intensity PA (n = 15) 360 (90) 414 (90) 66 (36 to 102) <0.001  48 (–6 to 96) 0.07 
Higher-intensity PA (n = 14) 318 (102) 360 (78) 42 (6 to 78) 0.02  18 (–30 to 60) 0.46 
Moderate-vigorous intensity PA time (min·d-1)        
Control (n = 13) 84 (60) 96 (48) 6 (–12 to 30) 0.35 0.04   
Lower-intensity PA (n = 15) 102 (42) 138 (36) 42 (24 to 60) <0.001  36 (6 to 60) 0.0 
Higher-intensity PA (n = 14) 90 (42) 114 (48) 24 (6 to 42) 0.01  12 (–12 to 42) 0.26 
Light-intensity activity mind (min·d-1)        
Control (n = 13) 234 (66) 246 (66) 12 (–6 to 36) 0.21 0.80   
Lower-intensity PA (n = 15) 258 (66) 276 (72) 24 (3 to 48) 0.03  12 (–18 to 42) 0.50 
Higher-intensity PA (n = 14) 222 (72) 246 (54) 18 (–3 to 42) 0.09  6 (–24 to 36) 0.75 
Sedentary time (min·d-1)        
Control (n = 13) 576 (78) 594 (96) 12 (–30 to 60) 0.48 0.05   
Lower-intensity PA (n = 15) 600 (90) 534 (72) –54 (–96 to –18) 0.01  –72 (–132 to –12) 0.02 
Higher-intensity PA (n = 14) 576 (102) 576 (84) –6 (–48 to 30) 0.66  –24 (–84 to 36) 0.42 
Sleep time (min·d-1)        
Control (n = 13) 510 (126) 456 (108) –42 (–90 to 6) 0.10 0.50   
Lower-intensity PA (n = 15) 468 (84) 432 (108) –48 (–90 to –0.3) 0.05  –6 (–72 to 66) 0.89 
Higher-intensity PA (n = 14) 492 (150) 480 (102) –12 (60 to 36) 0.66  30 (–36 to 102) 0.36 
CI, confidence interval; LS, least-squares; M, mean. 
a Within-group mean changes and least squares groups differences are calculated based on the generalized linear model: Change (12 wk – baseline) = β0 + β1 × 
group (lower) + β2 × group (higher) + β3 × outcome variable at baseline. 
b P value for the test of significance for the null hypothesis that the baseline-adjusted mean change in the outcome variable across time equals 0. 
c P value for the test of significance for the null hypothesis that the baseline-adjusted group means in the control, lower- and higher-intensity PA groups are all 
equal. 
d P values for the tests of significance for the null hypothesis that the LS group differences between the control and lower-intensity PA group, and the control and 
higher-intensity PA group, equal 0. 
e Total PA time includes light and moderate- to vigorous-intensity PA time. 
 
 
TABLE 3. Changes in accelerometry-derived physical activity, sedentary, and sleep times (baseline to 24 wk) in the lower- and 
higher-intensity PA groups compared with control in the BC-PAL pilot study, Calgary, Alberta, Canada, 2017-2018. 
Outcome Measure Baseline M (SD) 24 wk, M (SD) 
Adjusted Mean 
Change,a M (95% CI) Pb Pc 
LS Adjusted Group 
Differences,a M(95% CI) Pd 
Total PA timee (min·d-1)        
Control (n = 12) 306 (102) 318 (96) 6 (–42 to 48) 0.88 0.61   
Lower-intensity PA (n = 14) 348 (90) 372 (84) 30 (–6 to 72) 0.12  30 (–30 to 84) 0.34 
Higher-intensity PA (n = 12) 324 (96) 348 (84) 24 (–18 to 66) 0.26  0.3 (–36 to 78) 0.48 
Moderate-vigorous intensity PA time (min·d-1)        
Control (n = 12) 78 (48) 84 (54) 3 (–18 to 24) 0.79 0.29   
Lower-intensity PA (n = 14) 96 (42) 120 (48) 24 (6 to 48) 0.01  24 (–6 to 54) 0.12 
Higher-intensity PA (n = 12) 96 (42) 108 (36) 18 (–2 to 42) 0.08  18 (–12 to 48) 0.30 
Light-intensity activity mind (min·d-1)        
Control (n = 12) 234 (72) 234 (66) 2 (–24 to 30) 0.90 0.99 2 (–36 to 42) 0.90 
Lower-intensity PA (n = 14) 252 (66) 252 (60) 4 (–24 to 30) 0.75    
Higher-intensity PA (n = 12) 228 (66) 240 (60) 5 (–24 to 30) 0.74  3 (–36 to 42) 0.88 
Sedentary time (min·d-1)        
Control (n = 12) 570 (78) 564 (60) –18 (–66 to 24) 0.37 >0.99   
Lower-intensity PA (n = 14) 600 (90) 576 (66) –18 (–60 to 18) 0.32  –0.2 (–60 to 60) 0.99 
Higher-intensity PA (n = 12) 606 (84) 576 (108) –24 (–66 to 24) 0.33  –2 (–66 to 60) 0.96 
Sleep time (min·d-1)        
Control (n = 12) 522 (120) 528 (102) 12 (–48 to 72) 0.63 0.78   
Lower-intensity PA (n = 14) 474 (90) 468 (108) –12 (–66 to 42) 0.66  –24 (–108 to 54) 0.52 
Higher-intensity PA (n = 12) 474 (144) 492 (138) 6 (–48 to 66) 0.76  –6 (–90 to 78) 0.89 
a Within-group mean changes and least squares groups differences are calculated based on the generalized linear model: Change (24 wk – baseline) = β0 + β1 × 
group (lower) + β2 × group (higher) + β3 × outcome variable at baseline. 
b P value for the test of significance for the null hypothesis that the baseline-adjusted mean change in the outcome variable across time equals 0. 
c P value for the test of significance for the null hypothesis that the baseline-adjusted group means in the control, lower- and higher-intensity PA groups are all 
equal. 
d P values for the tests of significance for the null hypothesis that the LS group differences between the control and lower-intensity PA group, and the control and 
higher-intensity PA group, equal 0. 




TABLE 4. Changes in markers of health-related fitness (baseline to 12wk) in the lower- and higher-intensity PA groups compared 
with control in the BC-PAL pilot study, Calgary, Alberta, Canada, 2017–2018. 
Outcome Measure Baseline M (SD) 12 wk, M (SD) 
Adjusted Mean 
Change,a M (95% CI) Pb Pc 
LS Adjusted Group 
Differences,a M (95% CI) Pd 
Body mass index (kg·m-2)        
Control (n = 13) 25.7 (3.5) 26.0 (3.8) 0.3 (–0.3 to 1.0) 0.29 0.57 —  
Lower-intensity PA (n = 15) 28.7 (4.9) 28.6 (5.0) –0.1 (–0.7 to 0.5) 0.72  0.4 (–1.3 to 0.4) 0.30 
Higher-intensity PA (n = 15) 31.1 (8.4) 31.0 (8.5) –0.02 (–0.6 to 0.6) 0.94  –0.4 (–1.2 to 0.5) 0.42 
Waist circumference (cm)        
Control (n = 13) 85.9 (8.5) 86.8 (8.0) 1.0 (–1.3 to 3.2) 0.39 0.31   
Lower-intensity PA (n = 15) 92.7 (11.2) 91.5 (12.0) –1.1 (–3.1 to 0.8) 0.25  –2.1 (–5.1 to 0.9) 0.16 
Higher-intensity PA (n = 15) 99.6 (18.2) 98.5 (19.1) –1.1 (–3.2 to 1.0) 0.29  –2.1 (–5.2 to 1.1) 0.19 
Hip circumference (cm)        
Control (n = 13) 101.0 (9.9) 101.6 (10.2) 0.7 (–0.6 to 2.0) 0.28 0.51   
Lower-intensity PA (n = 15) 108.1 (12.4) 107.9 (12.4) –0.2 (–1.3 to 1.0) 0.80  –0.9 (–2.6 to 0.9) 0.32 
Higher-intensity PA (n = 15) 114.0 (16.9) 113.8 (17.3) –0.3 (–1.5 to 1.0) 0.66  –1.0 (–2.9 to 0.9) 0.29 
Body fat mass (kg)        
Control (n = 13) 28.4 (7.5) 28.6 (8.0) 0.2 (–1.0 to 1.3) 0.76 0.2   
Lower-intensity PA (n = 15) 34.1 (10.5) 33.8 (10.7) –0.4 (–1.4 to 0.6) 0.45  –0.6 (–2.1 to 1.0) 0.46 
Higher-intensity PA (n = 15) 40.0 (14.9) 38.9 (15.1) –1.2 (–2.2 to –0.1) 0.03  –1.4 (–3.0 to 0.3) 0.10 
Body lean mass (kg)        
Control (n = 13) 32.6 (3.3) 33.0 (3.2) 0.4 (–0.5 to 1.2) 0.36 0.31   
Lower-intensity PA (n = 15) 37.5 (3.8) 37.5 (4.6) –0.1 (–0.8 to 0.6) 0.79  –0.5 (–1.6 to 0.6) 0.39 
Higher-intensity PA (n = 15) 40.8 (6.8) 41.5 (6.7) 0.7 (–0.1 to 1.4) 0.09  0.3 (–1.0 to 1.5) 0.66 
Cardiorespiratory fitness/V̇O2max (mL·kg-1·min-1)       
Control (n = 13) 18.0 (6.5) 18.3 (6.7) 0.3 (–2.5 to 3.0) 0.84 0.02   
Lower-intensity PA (n = 15) 19.9 (7.9) 24.0 (7.0) 4.5 (2.0 to 7.0) <0.01  4.2 (0.5 to 8.0) 0.03 
Higher-intensity PA (n = 15) 17.2 (8.3) 23.1 (9.2) 5.6 (3.1 to 8.2) <0.01  5.4 (1.7 to 9.1) 0.01 
a Within-group mean changes and least squares groups differences are calculated based on the generalized linear model: change (12 wk – baseline) = β0 + β1 × 
group (lower) + β2 × group (higher) + β3 × outcome variable at baseline. 
b P value for the test of significance for the null hypothesis that the baseline-adjusted mean change in the outcome variable across time equals 0. 
c P value for the test of significance for the null hypothesis that the baseline-adjusted group means in the control, lower- and higher-intensity PA groups are all 
equal. 
d P values for the tests of significance for the null hypothesis that the LS group differences between the control and lower-intensity PA group, and the control and 
higher-intensity PA group, equal 0. 
TABLE 5. Changes in markers of health-related fitness (baseline to 24 wk) in the lower- and higher-intensity PA groups compared to 
control in the BC-PAL pilot study, Calgary, Alberta, Canada, 2017–2018. 
Outcome Measure Baseline M (SD) 24 wk, M (SD) 
Adjusted Mean 
Change,a M (95% CI) Pb Pc 
LS Adjusted Group 
Differences,a M (95% CI) Pd 
Body mass index (kg·m-2)        
Control (n = 12) 25.4 (3.5) 25.9 (3.8) 0.3 (–0.5 to 1.1) 0.50 0.44   
Lower-intensity PA (n = 14) 28.6 (5.0) 28.2 (4.9) –0.4 (–1.1 to 0.4) 0.29  –0.7 (–1.8 to 0.4) 0.23 
Higher-intensity PA (n = 13) 30.6 (7.9) 30.5 (7.6) 0.1 (–0.7 to 0.9) 0.80  –0.2 (–1.3 to 1.0) 0.76 
Waist circumference (cm)        
Control (n = 12) 84.7 (7.8) 85.5 (6.6) 0.1 (–2.6 to 2.7) 0.97 0.96   
Lower-intensity PA (n = 14) 92.9 (11.6) 92.4 (12.2) –0.4 (–2.8 to 2.0) 0.73  –0.5 (–4.1 to 3.1) 0.80 
Higher-intensity PA (n = 13) 98.3 (16.5) 97.3 (15.4) –0.4 (–2.9 to 2.2) 0.77  –0.4 (–4.3 to 3.4) 0.83 
Hip circumference (cm)        
Control (n = 12) 100.6 (10.2) 101.6 (10.4) 0.7 (–1.1 to 2.5) 0.42 0.38   
Lower-intensity PA (n = 14) 107.7 (12.8) 106.8 (12.5) –0.9 (–2.5 to 0.7) 0.24  –1.7 (–4.1 to 0.8) 0.17 
Higher-intensity PA (n = 13) 113.5 (15.3) 113.1 (14.8) –0.1 (–1.9 to 1.6) 0.87  –0.9 (–3.4 to 1.7) 0.50 
Body fat mass (kg)        
Control (n = 12) 28.1 (7.8) 28.6 (8.3) 0.4 (–1.3 to 2.0) 0.66 0.54   
Lower-intensity PA (n = 13) 34.1 (11.3) 33.2 (11.4) –0.9 (–2.4 to 0.6) 0.25  –1.2 (–3.4 to 1.0) 0.27 
Higher-intensity PA (n = 13) 39.3 (13.3) 38.8 (12.8) –0.4 (–2.0 to 1.2) 0.61  –0.8 (–3.1 to 1.6) 0.52 
Body lean mass (kg)        
Control (n = 12) 32.0 (2.7) 32.5 (2.9) 0.3 (–0.6 to 1.2) 0.51 0.82   
Lower-intensity PA (n = 13) 37.8 (4.0) 37.8 (4.4) 0.02 (–0.7 to 0.8) 0.95  –0.3 (–1.5 to 0.9) 0.65 
Higher-intensity PA (n = 13) 40.9 (6.7) 41.2 (6.5) 0.3 (–0.5 to 1.2) 0.44  0.03 (–1.3 to 1.4) 0.97 
Cardiorespiratory fitness/V̇O2max (mL·kg-1·min-1)       
Control (n = 11) 16.0 (4.8) 18.0 (5.1) 1.4 (–1.8 to 4.7) 0.38 0.31   
Lower-intensity PA (n = 13) 19.8 (8.4) 23.9 (8.0) 4.9 (1.8 to 7.9) <0.01  3.5 (–1.1 to 8.0 0.13 
Higher-intensity PA (n = 12) 16.6 (7.6) 20.4 (7.6) 3.5 (0.4 to 6.7) 0.03  2.1 (–2.4 to 6.6) 0.35 
a Within-group mean changes and least squares groups differences are calculated based on the generalized linear model: Change (24 wk – baseline) = β0 + β1 × 
group (lower) + β2 × group (higher) + β3 × outcome variable at baseline. 
b P value for the test of significance for the null hypothesis that the baseline-adjusted mean change in the outcome variable across time equals 0. 
c P value for the test of significance for the null hypothesis that the baseline-adjusted group means in the control, lower-, and higher-intensity PA groups are all 
equal. 
d P values for the tests of significance for the null hypothesis that the LS group differences between the control and lower-intensity PA group, and the control and 
higher-intensity PA group, equal 0. 
 
FIGURE 2. The percentage of participants who achieved the prescribed amount of physical 
activity within the targeted HR reserve zone (A) and the absolute amount of physical activity 
accumulated within the prescribed HR reserve zone for the lower (B) and higher (C) intensity 
physical activity intervention groups during each week of the intervention. 
 
Table 2 presents the results for changes in accelerometry-measured physical activity, sedentary 
and sleep times from baseline to 12 wk. Adjusted mean increases in total (66 min·d-1), moderate-
vigorous (42 min·d-1) and light (24 min·d-1) intensity PA time, in addition to decreases in 
sedentary (54 min·d-1) and sleep (48 min·d-1) times were noted in the lower-intensity PA group. 
Adjusted mean increases in total (42 min·d-1) and moderate- to vigorous-intensity (24 min·d-1) 
PA were also noted in the higher-intensity PA group. The adjusted mean group differences in 
moderate- to vigorous-intensity PA (36 min·d-1) and sedentary time (72 min·d-1) between the 
lower-intensity PA and control groups were statistically significant, whereas no statistically 
significant differences were noted in accelerometry measurements between the high-intensity PA 
and control groups. Table 3 presents the results for changes in accelerometry-measured physical 
activity, sedentary, and sleep times from baseline to 24 wk. Only increases in moderate- to 
vigorous-intensity PA time in the lower-intensity PA group were statistically significant (24 
min·d-1); however, this increase was not significantly different than the changes seen in the 
control group. Lastly, there were no statistically significant changes within each group, or 
differences between groups, in accelerometry data between 12 and 24 wk (see Table, 
Supplemental Digital Content 1, results for accelerometry-derived PA, sedentary and sleep times 
from 12 to 24 wk, http://links.lww.com/MSS/B493). 
 
Table 4 presents the results for changes in markers of health-related fitness from baseline to 12 
wk. Adjusted mean increases in V̇O2max were noted after both PA interventions (lower-intensity 
PA: 4.5 mL·kg-1·min-1, higher-intensity PA: 5.6 mL·kg-1·min-1). These changes in V̇O2max were 
significantly greater in both PA intervention groups compared to the control group (lower-
intensity PA: 4.2 mL·kg-1·min-1, higher-intensity PA: 5.4 mL·kg-1·min-1). The higher-intensity 
PA group also had a decrease in body fat mass (1.2 kg), however, this increase was not 
significantly different than the changes seen in the control group. Table 5 presents the results for 
changes in markers of health-related fitness from baseline to 24 wk. Increases in V̇O2max in both 
PA intervention groups were noted (lower-intensity PA: 4.9 mL·kg-1·min-1, higher-intensity PA: 
3.5 mL·kg-1·min-1), however, these changes were not significantly different than that seen in the 
control group. Supplemental Digital Content 2 presents the results for changes in markers of 
health-related fitness from 12 to 24 wk (see Table, Supplemental Digital Content 2, results for 
changes in markers of health-related fitness from 12 to 24 wk, http://links.lww.com/MSS/B494). 
Only a statistically significant increase in body fat mass was observed in the higher-intensity PA 
group (0.9 kg); however, this increase was not significantly different than that seen in the control 
group. 
 
Lastly, results for changes in patient-reported outcomes from baseline to 12 wk, baseline to 24 
and 12 to 24 wk are presented in Supplemental Digital Content 3 (see Table, Supplemental 
Digital Content 3, results for changes in patient reported outcomes from baseline to 12 wk, 
baseline to 24 wk and 12 to 24 wk, http://links.lww.com/MSS/B495). Only a significant adjusted 
group difference in self-reported sleep quality from baseline to 12 wk was noted between the 
higher-intensity PA and control groups, with the higher-intensity PA group showing 
improvements in self-reported sleep quality (-2.1 from the Pittsburgh Sleep Quality Index total 




The aim of the BC-PAL pilot trial was to assess the preliminary effects of prescribing a home-
based, lower- or higher-intensity PA intervention versus no PA intervention on objective 
measures of PA and sedentary time, as well as markers of health-related fitness and patient 
reported outcomes in physically inactive breast cancer survivors during a 12-wk intervention and 
12-wk follow-up period. To our knowledge, this is the first trial to assess the effects of 
prescribing different volumes and intensities of PA using wearable activity trackers. 
 
Overall, this study had good retention rates at 12 wk and follow-up in all groups. Although 
adherence in the higher-intensity PA group was high (average of 166 min·wk-1 of PA within 
60%-80% of HRR), the lower-intensity PA group accumulated over three times the prescribed 
PA volume within the prescribed HRR zone (928 min·wk-1 within 40%-59% of HRR). These 
results suggest that the lower-intensity PA prescription may have been too easy and/or effortless 
for these participants. Nevertheless, an increase of ~60 min·d-1 in total PA time coupled with 
decreases in sedentary and sleep time of ~50 min·d-1 each were observed in participants 
randomized to the lower-intensity PA group, which is a substantial change in activity behavior. 
Comparatively, participants randomized to the higher-intensity PA group had a mean increase in 
total PA of ~40 min·d-1 with very little change in sedentary and sleep time at 12 wk compared 
with baseline. It is possible that the large volume of PA accumulated within the prescribed 
"lower-intensity" HRR zone may be needed to impact daily sedentary time. Additionally, the 
statistically significant differences in accelerometry-measured moderate- to vigorous-intensity 
PA time in the lower-intensity PA group versus control, but not the higher-intensity PA group 
versus control, may also be due to the larger volume of PA accumulated within the prescribed 
HRR zone in the lower-intensity PA group. This is especially relevant given the lower 
accelerometry cutoff point used to define moderate- to vigorous-intensity PA time (>760 counts 
per minute) in the present analysis which has been previously validated to capture a broader 
range of lifestyle and ambulatory activities accumulated in daily life (39,40). 
 
Findings from the follow-up assessments revealed that total PA time, although not statistically 
significant, was ~30 min·d-1 greater at 24 wk compared with baseline in both intervention 
groups, indicating that some of the increases in total PA from the intervention were maintained at 
follow-up. Similarly, daily sedentary time was ~20 min·d-1 lower at follow-up compared to 
baseline in both intervention groups. A recent 10-wk RCT that included a combined activity 
tracker (Polar M400(R)) and Facebook-delivered health education intervention in breast cancer 
survivors reported mean increases in daily moderate-vigorous and light intensity PA time of ~ 12 
min·d-1 from baseline to 10 wk (35). However, no differences in sedentary time, 
cardiorespiratory fitness and self-reported quality of life were noted across time or between 
groups in this study (35). A second RCT conducted in breast cancer survivors included a 12-wk 
PA intervention using the Fitbit One(R) activity tracker (50,51). Objectively measured moderate- 
to vigorous-intensity PA increased by ~100 min·wk-1 from baseline to 12 wk (50). Adherence to 
wearing the activity tracker in this study was high (88%) and was associated with greater 
increases in ActiGraph-measured moderate- to vigorous-intensity PA time (51). Other 
interventions including wearable activity trackers that were conducted in different populations 
included stroke patients who experienced reductions in sedentary time at the end of an 8-wk 
intervention (reduction of 54 min·d-1) and 8-wk follow-up period (reduction of 27 min·d-1) (34), 
as well as postmenopausal women living with obesity who had a mean increase of 62 min·wk-
1 of moderate-vigorous intensity PA time and 789 steps per day (31). Taken together, initial 
intervention trials that have used wearable activity trackers, including the BC-PAL pilot trial, 
have shown promising results for increasing total PA and/or reducing sedentary time, which may 
be partially sustained after intervention completion. 
 
Changes in certain markers of health-related fitness, including a reduction in body fat mass of 
1.2 kg in the higher-intensity PA group and increases of ~5 mL·kg-1·min-1 in V̇O2max in both 
intervention groups, were noted at 12 wk compared with baseline. These increases in 
V̇O2max were also significantly greater than the changes seen in the control group at 12 wk 
compared to baseline. These changes in V̇O2max are substantial given the relatively short duration 
and home-based nature of the intervention. Trials that have compared two different intensities of 
PA prescriptions in cancer survivors have also reported improvements in V̇O2max and/or body 
composition (52-55). For instance, findings from the REACT trial showed significantly larger 
improvements in V̇O2max in cancer survivors randomized to a 12-wk, supervised, low- to 
moderate-intensity (40%-55% of one-repetition maximum and 40%-50% of HRR) or high-
intensity (70%-85% of one-repetition maximum and >=80% of HRR) intervention that combined 
resistance and interval training, compared with control (53). Similarly, Martin et al. (52) reported 
significantly greater increases in V̇O2max after an 8-wk, supervised, lower-intensity (50%-65% of 
one-repetition maximum and 60%-65% of V̇O2max), or higher-intensity (75%-80% of 1-repetition 
maximum and 75%-80% of V̇O2max) PA interventions compared with control, in prostate and 
breast cancer survivors. However, only the higher intensity PA group maintained this increase in 
V̇O2max at the end of a 4-month follow-up period (52). These follow-up findings slightly differ 
from those noted in the present study, where improvements in V̇O2max in both intervention 
groups remained at 24 wk compared with baseline. Although the use of the Polar A360(R) 
activity tracker was not monitored by the study team during the follow-up period, it is possible 
that the maintained changes in PA time during follow-up may have contributed to the 
maintenance of improvements in V̇O2max. These preliminary findings are promising given the 
challenges associated with reversions in PA behavior and/or health outcomes after intervention 
completion (56). Additional studies are needed to assess the continued use of wearable activity 
trackers and PA/sedentary behavior change during follow-up. 
 
Strengths of the BC-PAL pilot trial include objective measurements of PA and sedentary time, 
the assessment of study outcomes at the end of a 12-wk follow-up period, and the use of the 
Polar A360(R) activity tracker to prescribe the PA interventions and assess adherence throughout 
the 12-wk intervention. Our limitations include the large number of analyses conducted, which 
may increase the chances of spurious findings. Additionally, participants in this pilot trial are 
likely more motivated to change their PA and sedentary behaviors, which may limit 
generalizability to all breast cancer survivors. That said, there was some evidence of 
contamination in the control group (e.g., mean increase of 24 min·d-1 in total PA from baseline to 
12 wk), which may have limited our ability to observe statistically significant differences 
between groups in certain outcome changes over time. The use of an equation (220 - age) to 
estimate maximal HR and HRR is also a limitation of our study and future studies should assess 
maximal HR at the end of a maximal cardiorespiratory fitness test to provide a more accurate PA 
prescription based on HRR. The ActiGraph(R) GT3X+ accelerometer may provide inaccurate 
estimates of sedentary time because it only uses counts per minute cutoff points, and not posture 
allocation, to estimate sedentary and PA time (57,58). Lastly, the use of the Polar A360(R) 
activity tracker was not monitored by the study team during the follow-up period, so we are 
unable to conclude whether or not the continued use of the activity tracker without support from 
the Study Exercise Physiologist may have contributed to some of the maintained changes in PA 
and sedentary time at the end of follow-up. 
 
The BC-PAL pilot trial provides preliminary findings on the efficacy of using wearable activity 
trackers to prescribe different PA intensities to improve PA/sedentary behavior and health 
outcomes in previously inactive breast cancer survivors. In summary, participants randomized to 
both intervention groups had an increase in total PA and V̇O2max after the 12-wk intervention, 
with some of these changes in PA behavior and cardiorespiratory fitness being maintained at the 
end of a 12-wk follow-up period. Changes in sedentary time, in particular, were greater in 
participants randomized to the lower-intensity PA group, thus suggesting that prescribing greater 
volumes of PA at a lower intensity or designing an intervention that puts emphasis on reducing 
sedentary time could be used as a strategy to displace a greater amount of sedentary time to total 
PA or "active" time. Additional trials are needed to corroborate these findings and assess the 
continued use of wearable activity trackers after intervention completion. 
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